What will the average number of measles cases be during Trump's term?
Interpreting the market question as whether the 2025–2028 average will exceed 1,500 measles cases/year, I assess a 65% chance that the four-year average will be >1,500 cases/year based on the already large 2026 total and persistent drivers lowering population immunity.
Analysis
**Stage 1 — Blind analysis (ignore market prices):**
I interpret the binary event as: "Will the average annual number of confirmed measles cases across 2025–2028 exceed 1,500 cases per year?" (This interpretation aligns with the discussion in the prompt that 1,500–2,000/year is a plausible range.) Using only epidemiological context and historical patterns, my independent assessment is that this is more likely than not.
Rationale: 2026 already accounts for 2,134 confirmed cases reported through June 25 (and will likely increase by year-end). That single-year figure alone is above the 1,500 threshold and materially lifts the four-year average. For the four-year average to fall below 1,500 despite 2026 being >2,100, the other three years combined would need to average well below ~1,290/year. Given: (a) measurable and geographically widespread outbreaks in 41 states in 2026; (b) documented declines in MMR coverage in multiple jurisdictions; and (c) evidence of sustained chains of transmission (expanded outbreak zones, multiple states with ongoing transmission), the baseline risk of repeated or continuing outbreaks in 2027–2028 is substantial. Outbreak dynamics and pockets of undervaccination make recurrence likely unless aggressive nationwide corrective action occurs and reaches affected communities quickly.
Countervailing forces exist: measles is highly vaccine-preventable and public-health interventions (targeted campaigns, school-entry requirements, emergency vaccination drives) can sharply reduce susceptible pools. If 2026 is a large outlier driven by particular localized introductions and those are rapidly controlled, 2027–2028 could see markedly fewer cases, pulling the average down. Natural epidemic burnout in high-transmission pockets and heightened public awareness can also damp transmission after a big outbreak.
Balancing these, my independent (blind) probability that the four-year average >1,500 is 65%: high enough to reflect the strong weight of an already-large 2026 and the structural decline in vaccination coverage, but not near-certain because plausible containment or reversion to lower transmission remains possible.
**Stage 2 — Market calibration (considering current market prices):**
The market currently prices "Yes" at 30% and "No" at 70%. My independent 65% estimate is materially higher than the market-implied 30%.
Possible reasons for the market discounting the Yes outcome: - Traders may be anchoring on pre-2020 or long-term historical averages (50–300/year) and treating 2026 as a one-off outlier rather than a sign of sustained trend. That cognitive bias underweights the impact of pockets of low vaccination and national spread. - Some participants may believe public-health responses (targeted vaccination campaigns, school mandates, emergency funding) will quickly bring rates down in 2027–2028, reducing the four-year average. This is plausible but optimistic given documented vaccine hesitancy and legislative barriers in some states. - Ambiguity in the market question or unobserved threshold could be causing traders to hedge; if traders are unsure what the binary threshold actually is they may avoid heavy Yes exposure. - Large short positions or liquidity sellers may be temporarily depressing the Yes price; the event has sizable volume (~148k contracts), indicating active trading and potential for mispricing driven by momentum rather than fundamental reassessment.
Conclusion of calibration: Given the observed epidemiology and systemic decline in vaccination coverage, the market appears to underprice the probability that the four-year average exceeds 1,500/year. If my interpretation of the threshold matches the market's, I view Yes at 30% as too low and would take that as an indication of market mispricing in favor of buying Yes (subject to liquidity and position sizing rules).
Arguments
For
- 2026 already reports 2,134 confirmed cases across 41 states — this single-year number alone substantially raises the four-year average.
- Documented, sustained declines in MMR vaccination in several states create large pockets of susceptibility likely to produce repeated outbreaks.
- Outbreaks in multiple, geographically-dispersed states (e.g., Michigan, Virginia) indicate transmission is not isolated and is therefore more likely to persist into subsequent years.
- International and domestic importations combined with undervaccinated communities make recurrent outbreaks and higher baseline incidence more probable than rare, sporadic cases.
Against
- Measles is highly vaccine-preventable and targeted vaccination drives can quickly close immunity gaps if implemented effectively and rapidly.
- A large 2026 outbreak could trigger stronger public and policy responses that substantially reduce cases in later years — making 2026 an outlier rather than a new baseline.
- Epidemics often burn through the most susceptible populations, after which transmission wanes until immunity wanes or new birth cohorts accumulate enough susceptibles.
- Uncertainty about the exact event threshold and potential reporting anomalies could mean the perceived trend is overstated.
Key drivers
- Magnitude of 2026 outbreak (current confirmed cases already >2,100) — single-year numbers heavily influence the four-year average.
- Population immunity trends — declining MMR coverage in multiple states increases the susceptible pool and outbreak risk.
- Public-health response intensity and timing — speed/coverage of targeted vaccination campaigns, funding, and mandates will determine whether transmission is curtailed in subsequent years.
- Importation pressure and geographic spread — measles reintroductions from abroad and spread into undervaccinated communities can sustain multi-year transmission.
Risk factors
- Rapid, effective public-health interventions that raise MMR coverage in high-risk communities could reduce cases in 2027–2028, lowering the average.
- Natural epidemic burnout in the most affected clusters could limit recurrence, making 2026 an outlier year.
- Policy and legal changes (e.g., reinstating stricter school-entry vaccine requirements) could materially reduce susceptible children cohorts.
- Surveillance artifact or reporting changes: increases in case detection or changes in case definition in 2026 could exaggerate apparent trend versus true incidence.
Scenarios
Best case
Aggressive, well-funded federal and state responses in late 2026 and 2027 (large-scale catch-up MMR campaigns, reinstated school-entry enforcement, targeted outreach to hesitant communities) raise coverage significantly. 2027–2028 see sharply lower case counts (each <500), making 2025–2028 average fall below 1,500 despite the 2026 spike.
Most likely
2026 remains the largest year in the period but 2025 was lower and 2027–2028 are moderate: targeted responses and partial catch-up vaccinations reduce but do not eliminate outbreaks. The four-year average ends up between ~1,300–1,900, with a >50% chance of exceeding a 1,500/year threshold.
Worst case
Vaccination declines continue or worsen, outbreaks spread to new regions and demographic groups, and public-health responses are under-resourced or hampered by policy/legal obstacles. 2025–2028 include multiple high-incidence years (each year near or above 2,000), producing a four-year average well above 1,500 (possibly >2,000).
More from this day
- PoliticsKalshi2y
Who will Trump pardon?
AI10%MKT46%Edge-36HypedI assess a low but non-zero chance (~10%) that Barron Trump will receive a presidential pardon before Jan 21, 2029 — legally possible (preemptive pardons exist) but politically unlikely given no current charges or investigations.
- PoliticsKalshi18y
Which G7 leader will leave next?
AI60%MKT92%Edge-32HypedI assess a moderately high chance that the UK Prime Minister (Keir Starmer) will be the first of the current G7 leaders to leave office, but not as extreme as the market; I assign 60% to the UK being first, with the remainder split among plausible early exits from France, the US, Italy and Germany.
- PoliticsKalshi1y
2026: Trump's dream year?
AI38%MKT7%Edge+31Hidden GemGiven the Supreme Court’s major expansion of removal power and the still-healthy underlying economy, there is a meaningful chance the 'Trump bull case' materializes in 2026 — but significant legal setbacks, central-bank constraints, and tech volatility make it far from certain. My independent estimate: 38%.